219 related articles for article (PubMed ID: 25850767)
1. Molecular and cellular pathways as treatment targets for biologic therapies in systemic sclerosis.
Dimitroulas T; Daoussis D; Garyfallos A; Sfikakis PP; Kitas GD
Curr Med Chem; 2015; 22(16):1943-55. PubMed ID: 25850767
[TBL] [Abstract][Full Text] [Related]
2. Innovative antifibrotic therapies in systemic sclerosis.
Beyer C; Distler O; Distler JH
Curr Opin Rheumatol; 2012 May; 24(3):274-80. PubMed ID: 22450392
[TBL] [Abstract][Full Text] [Related]
3. [B cell abnormalities and therapeutic strategies in systemic sclerosis].
Yoshizaki A
Nihon Rinsho Meneki Gakkai Kaishi; 2016; 39(3):197-206. PubMed ID: 27320935
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis.
Denton CP; Ong VH; Xu S; Chen-Harris H; Modrusan Z; Lafyatis R; Khanna D; Jahreis A; Siegel J; Sornasse T
Ann Rheum Dis; 2018 Sep; 77(9):1362-1371. PubMed ID: 29853453
[TBL] [Abstract][Full Text] [Related]
5. Potential immunologic targets for treating fibrosis in systemic sclerosis: a review focused on leukocytes and cytokines.
Hasegawa M; Takehara K
Semin Arthritis Rheum; 2012 Dec; 42(3):281-96. PubMed ID: 22542279
[TBL] [Abstract][Full Text] [Related]
6. Emerging diagnostic and therapeutic challenges for skin fibrosis in systemic sclerosis.
Abraham D; Lescoat A; Stratton R
Mol Aspects Med; 2024 Apr; 96():101252. PubMed ID: 38325132
[TBL] [Abstract][Full Text] [Related]
7. Paquinimod reduces skin fibrosis in tight skin 1 mice, an experimental model of systemic sclerosis.
Stenström M; Nyhlén HC; Törngren M; Liberg D; Sparre B; Tuvesson H; Eriksson H; Leanderson T
J Dermatol Sci; 2016 Jul; 83(1):52-9. PubMed ID: 27156795
[TBL] [Abstract][Full Text] [Related]
8. Future targets in the management of systemic sclerosis.
Tyndall A; Matucci-Cerinic M; Müller-Ladner U
Rheumatology (Oxford); 2009 Jun; 48 Suppl 3():iii49-53. PubMed ID: 19487225
[TBL] [Abstract][Full Text] [Related]
9. Systemic sclerosis: from pathogenesis to targeted therapy.
Denton CP
Clin Exp Rheumatol; 2015; 33(4 Suppl 92):S3-7. PubMed ID: 26457375
[TBL] [Abstract][Full Text] [Related]
10. Current immunosuppressive and antifibrotic therapies of systemic sclerosis and emerging therapeutic strategies.
Fallet B; Walker UA
Expert Rev Clin Pharmacol; 2020 Nov; 13(11):1203-1218. PubMed ID: 33008265
[TBL] [Abstract][Full Text] [Related]
11. Systemic sclerosis and localized scleroderma--current concepts and novel targets for therapy.
Distler O; Cozzio A
Semin Immunopathol; 2016 Jan; 38(1):87-95. PubMed ID: 26577237
[TBL] [Abstract][Full Text] [Related]
12. Nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease.
Yamasaki Y; Kuwana M
Expert Rev Clin Immunol; 2020 Jun; 16(6):547-560. PubMed ID: 32506975
[TBL] [Abstract][Full Text] [Related]
13. Antifibrotics in systemic sclerosis.
Martin-Lopez M; Carreira PE
Best Pract Res Clin Rheumatol; 2021 Sep; 35(3):101671. PubMed ID: 33839046
[TBL] [Abstract][Full Text] [Related]
14. Early inflammatory players in cutanous fibrosis.
Raker V; Haub J; Stojanovic A; Cerwenka A; Schuppan D; Steinbrink K
J Dermatol Sci; 2017 Sep; 87(3):228-235. PubMed ID: 28655471
[TBL] [Abstract][Full Text] [Related]
15. Rationally-based therapeutic disease modification in systemic sclerosis: Novel strategies.
Asano Y; Varga J
Semin Cell Dev Biol; 2020 May; 101():146-160. PubMed ID: 31859147
[TBL] [Abstract][Full Text] [Related]
16. Targeting Costimulatory Pathways in Systemic Sclerosis.
Boleto G; Allanore Y; Avouac J
Front Immunol; 2018; 9():2998. PubMed ID: 30619351
[TBL] [Abstract][Full Text] [Related]
17. Targeting vascular disease in systemic sclerosis.
Kowal-Bielecka O
Endocr Metab Immune Disord Drug Targets; 2006 Dec; 6(4):401-7. PubMed ID: 17214586
[TBL] [Abstract][Full Text] [Related]
18. Systemic sclerosis: a systematic review on therapeutic management from 2011 to 2014.
Young A; Khanna D
Curr Opin Rheumatol; 2015 May; 27(3):241-8. PubMed ID: 25775190
[TBL] [Abstract][Full Text] [Related]
19. Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature.
Giuggioli D; Lumetti F; Colaci M; Fallahi P; Antonelli A; Ferri C
Autoimmun Rev; 2015 Nov; 14(11):1072-8. PubMed ID: 26209905
[TBL] [Abstract][Full Text] [Related]
20. Systemic sclerosis: Recent insight in clinical management.
Zanatta E; Codullo V; Avouac J; Allanore Y
Joint Bone Spine; 2020 Jul; 87(4):293-299. PubMed ID: 31568838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]